Analyst Price Targets — NVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 26, 2026 12:09 pm | Thibault Boutherin | Morgan Stanley | $170.00 | $149.70 | TheFly | Novartis price target raised to $170 from $143 at Morgan Stanley |
| December 10, 2025 11:16 am | — | HSBC | $112.00 | $131.01 | TheFly | Novartis price target raised to $112 from $106 at HSBC |
| December 3, 2025 11:33 am | — | Morgan Stanley | $143.00 | $132.28 | TheFly | Novartis price target raised to $143 from $136 at Morgan Stanley |
| October 29, 2025 3:42 pm | Wan Nurhayati | CFRA | $126.00 | $123.33 | StreetInsider | Novartis (NVS) PT Raised to $126 at CFRA |
| October 30, 2024 8:48 am | Etzer Darout | BMO Capital | $120.00 | $109.91 | StreetInsider | Novartis (NVS) PT Raised to $120 at BMO Capital |
| September 5, 2024 4:27 am | James Quigley | Goldman Sachs | $121.00 | $119.38 | TheFly | Novartis downgraded to Neutral from Buy at Goldman Sachs |
| July 19, 2024 9:06 am | Etzer Darout | BMO Capital | $118.00 | $106.13 | StreetInsider | Novartis (NVS) PT Raised to $118 at BMO Capital |
| April 23, 2024 1:11 pm | Wan Nurhayati | CFRA | $108.00 | $97.27 | StreetInsider | Novartis (NVS) PT Raised to $108 at CFRA |
Latest News for NVS
Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their autoimmune CAR-T programmes following safety issues.
South Korea's Alteogen said on Wednesday it has signed a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous drugs.
Novartis (NVS), the Swiss pharmaceutical and oncology giant, rocketed approximately 6% to $161.10 Tuesday after remibrutinib cleared two major Phase 3 tests in
Novartis (NVS) has seen a significant increase in its stock price following the positive outcomes of remibrutinib in the Phase III REMODEL trials. The drug demo
Promising results from a recent clinical trial are boosting Novartis shares this morning.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for NVS.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.